Cardiff Oncology, Inc.
CRDF
$1.53
$0.032.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 525.00K | 593.00K | 501.00K | 546.00K | 588.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 525.00K | 593.00K | 501.00K | 546.00K | 588.00K |
| Cost of Revenue | 31.62M | 35.33M | 39.97M | 41.41M | 39.32M |
| Gross Profit | -31.09M | -34.74M | -39.47M | -40.86M | -38.73M |
| SG&A Expenses | 16.34M | 14.22M | 14.24M | 13.47M | 13.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.95M | 49.55M | 54.21M | 54.88M | 52.69M |
| Operating Income | -47.43M | -48.96M | -53.71M | -54.33M | -52.10M |
| Income Before Tax | -44.76M | -45.85M | -50.42M | -51.02M | -48.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.76 | -45.85 | -50.42 | -51.02 | -48.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.76M | -45.85M | -50.42M | -51.02M | -48.85M |
| EBIT | -47.43M | -48.96M | -53.71M | -54.33M | -52.10M |
| EBITDA | -47.07M | -48.60M | -53.33M | -53.95M | -51.71M |
| EPS Basic | -0.67 | -0.69 | -0.80 | -0.88 | -0.94 |
| Normalized Basic EPS | -0.42 | -0.43 | -0.50 | -0.55 | -0.58 |
| EPS Diluted | -0.67 | -0.69 | -0.80 | -0.88 | -0.94 |
| Normalized Diluted EPS | -0.42 | -0.43 | -0.50 | -0.55 | -0.58 |
| Average Basic Shares Outstanding | 269.19M | 267.36M | 254.15M | 234.13M | 212.43M |
| Average Diluted Shares Outstanding | 269.19M | 267.36M | 254.15M | 234.13M | 212.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |